Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2010 1
2011 1
2012 1
2015 1
2016 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

5 results

Results by year

Filters applied: . Clear all
Page 1
Cytogenetics in the management of myelodysplastic neoplasms (myelodysplastic syndromes, MDS): Guidelines from the groupe francophone de cytogenetique hematologique (GFCH).
Auger N, Douet-Guilbert N, Quessada J, Theisen O, Lafage-Pochitaloff M, Troadec MB. Auger N, et al. Curr Res Transl Med. 2023 Oct-Dec;71(4):103409. doi: 10.1016/j.retram.2023.103409. Epub 2023 Sep 17. Curr Res Transl Med. 2023. PMID: 38091642
Myelodysplastic neoplasms (MDS) are clonal hematopoietic neoplasms. Chromosomal abnormalities (CAs) are detected in 40-45% of de novo MDS and up to 80% of post-cytotoxic therapy MDS (MDS-pCT). ...The ICC maintains CA allowing the diagnosis of MDS without dysplasia ( …
Myelodysplastic neoplasms (MDS) are clonal hematopoietic neoplasms. Chromosomal abnormalities (CAs) are detected in 40-45% of de novo …
Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes.
Komrokji RS, List AF. Komrokji RS, et al. Ann Oncol. 2016 Jan;27(1):62-8. doi: 10.1093/annonc/mdv488. Epub 2015 Oct 26. Ann Oncol. 2016. PMID: 26504152 Free PMC article. Review.
The treatment of patients with myelodysplastic syndromes (MDS) begins with assessment of karyotype and risk. Lenalidomide is approved for the treatment of patients who have transfusion-dependent anemia due to lower-risk MDS with chromosome 5q deletion (del …
The treatment of patients with myelodysplastic syndromes (MDS) begins with assessment of karyotype and risk. Lenalidomide is a …
Changes associated with lenalidomide treatment in the gene expression profiles of patients with del(5q).
Belickova M, Cermak J, Dostalova Merkerova M, Vesela J, Krejcik Z, Cechova E, Zemanova Z, Michalova K, Votavova H, Caniga M, Neuwirtova R, Jonasova A. Belickova M, et al. Clin Lymphoma Myeloma Leuk. 2012 Oct;12(5):375-83. doi: 10.1016/j.clml.2012.04.003. Epub 2012 May 18. Clin Lymphoma Myeloma Leuk. 2012. PMID: 22608605
BACKGROUND: Lenalidomide is an effective treatment for patients with del(5q) and myelodysplastic syndrome (MDS) The exact mechanism of lenalidomide function and its impact on the prognosis of patients is not known exactly. MATERIALS AND METHODS: We use …
BACKGROUND: Lenalidomide is an effective treatment for patients with del(5q) and myelodysplastic syndrome (MDS) …
Current treatment options: impact of cytogenetics on the course of myelodysplasia.
Galili N, Cerny J, Raza A. Galili N, et al. Curr Treat Options Oncol. 2007 Apr;8(2):117-28. doi: 10.1007/s11864-007-0017-1. Curr Treat Options Oncol. 2007. PMID: 17634837 Review.
The heterogeneity of myelodysplastic syndromes (MDS) has driven the search for unifying biologic and clinical features that would stratify patients into distinct prognostic and therapeutic subgroups. ...Yet, as will be described below, specific cytogenetic ab …
The heterogeneity of myelodysplastic syndromes (MDS) has driven the search for unifying biologic and clinical features that wo …
Phenotypic abnormalities strongly reflect genotype in patients with unexplained cytopenias.
Cutler JA, Wells DA, van de Loosdrecht AA, de Baca ME, Kalnoski MH, Zehentner BK, Eidenschink L, Ghirardelli KM, Biggerstaff JS, Loken MR. Cutler JA, et al. Cytometry B Clin Cytom. 2011 May;80(3):150-7. doi: 10.1002/cyto.b.20582. Epub 2010 Dec 23. Cytometry B Clin Cytom. 2011. PMID: 21520402 Free article.
METHODS: In 431 patients presenting with unexplained cytopenia(s) FCM results were compared to abnormal karyotyping and FISH results recognized as associated with myelodysplastic syndrome (MDS) in the 2008 WHO classification, to assess the degree of and types …
METHODS: In 431 patients presenting with unexplained cytopenia(s) FCM results were compared to abnormal karyotyping and FISH results recogni …